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Abstract
Expression of p53 appears to be correlated to prognosis in patients with malignancy, but its role in gastric carcinoma has
remained controversial. Recently we reported that JWA, an ADP-ribosylation-like factor 6 interacting protein 5 (ARL6ip5),
was both prognostic for overall survival and predictive for platinum-based treatment of gastric cancer. In this study, we
aimed to investigate p53 expression as a prognostic and predictive marker in resectable gastric cancer, alone and in
combination with JWA. Expression of p53 was examined in three large patient cohorts (total n = 1155) of gastric cancer.
High expression of p53 was significantly correlated with unfavorable clinicopathologic parameters and decreased overall
patient survival. Furthermore, patients with high p53 expression in tumors acquired remarkable survival benefit from
adjuvant first-line platinum-based-chemotherapy. The synergy between p53 and JWA in predicting patient outcome was
demonstrated, while no significantly elevated predictive value concerning chemotherapy was observed. Thus, p53
expression is a potent prognostic and predictive factor for resectable gastric cancer with adjuvant platinum-based
chemotherapy. A combined effect of p53 with JWA as efficient prognostic indicators was found for the first time.
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Introduction
Gastric cancer affects about one million people a year, being the
second leading cause of cancer-related mortality worldwide with
an overall five-year survival rate of less than 30% [1]. The poor
outcome has remained basically unchanged over the last decades
in spite of improvements in surgical, chemo- and radiotherapy [2].
Striking differences in prognosis among patients after standard
surgery exist, indicating specific biomarkers are urgently needed
[3]. Moreover, selection of patients who will benefit from
chemotherapy is a major issue as a large fraction is unnessesarily
treated and only get severe side effects [4]. Thus, efficient
molecular markers are urgently needed to avoid over- or
undertreatment.
The p53 protein (encoded by the human gene TP53) is possibly
the best known of all tumor suppressors, and characterized by the
ability to induce cell cycle arrest, DNA repair, senescence, and
apoptosis [5]. Mutation or functional inactivation of p53 is an
almost universal feature of human cancer, playing a crucial role in
tumorigenesis since mutant p53 may acquire new oncogenic
properties [6–9]. Furthermore, unlike wild-type p53 protein that is
degraded rapidly, mutant forms have a prolonged half-life, which
favor intranuclear storage, becoming detectable immunohisto-
chemically [10–12]. The accumulation of p53 protein in the case
of gastric cancer has been linked to prognosis and prediction of
treatment [13,14]. However, its related role and mechanism
hitherto remain controversial [15,16].
Our recent findings implicated that JWA, also known as
ARL6ip5, similar with p53 in some aspects, is essential for cell
survival and efficient DNA repair after oxidative DNA damage, as
well as chemically induced cancer cell apoptosis [17,18].
Moreover, JWA and XRCC1, another DNA repair protein,
may be candidate prognostic and predictive biomarkers for
patients with gastric cancer [19]. Additionally, SNPs of the JWA
gene are associated with increased predisposition to gastric
carcinoma in a Chinese population [20]. Thus, we are consider-
ably interested if JWA would work as a cooperator with p53 to
improve predictive potency in gastric cancer.
Herein, we aimed to elucidate the translational significance and
identify the expression patterns of p53 in three large independent
cohorts of gastric cancer patients and to examine the possible
prognostic and predictive role of this marker. More intriguingly, a
hypothesis would be validated on whether p53 and JWA could be
combined as a novel predictor with more accuracy in survival
evaluation.
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Materials and Methods
Patients and Samples
Three independent retrospective patient cohorts were studied.
The training cohort and testing cohort were collected in Nantong
Cancer Hospital, Nantong City, in the east part of Jiangsu
Province and the validation cohort was recruited in Yixing
People’s Hospital, Yixing City, in the south part of Jiangsu
Province, China. The tissues were obtained from the respective
pathology divisions. Inclusion criteria were gastric carcinoma
treated with radical gastrectomy with or without adjuvant
chemotherapy. Exclusion criteria were patients with previous
gastric cancer or active non-gastric cancer. Also, those who
received pre-surgical chemo- or radiation therapy were excluded.
Written informed consent was obtained from each patient prior to
tissue acquisition and before surgery was carried out. Institutional
approval was acquired from the Ethical Review Board of Nanjing
Medical University prior to this study.
Patients Treated with Surgery Alone
The training cohort included 103 patients who only underwent
radical gastrectomy at Nantong Cancer Hospital from 1st May
1990 to 1st June 1995. However, 20 samples were omitted because
of missing data and one sample was lost during antigen retrieval or
without tumor cells present in the core, so 82 paired patient tissues
were finally evaluated for p53 expression.
The testing cohort consisted of all 640 surgical cases from the
Nantong Cancer Hospital from 1st December 2000 to 1st April
2005 and the validation cohort included all 1022 surgical cases in
Yixing People’s Hospital from 1st January 1999 to 31st December
2006. These patients were treated with surgery only or with
postoperative adjuvant chemotherapy (for details, see Fig. S1). The
distributions of demographic characteristics and the selected
clinicopathologic variables of patients between the two districts
(Nantong and Yixing) were described previously [19]. Due to
missing survival data, only 578 and 998 of these patients were
included. Furthermore, due to lost cores or insufficient tumor cells
in the tissue, 485 and 588 tumor cores were analyzed for p53
expression in the testing and validation cohort, respectively.
Patients Treated with Adjuvant Chemotherapy
In the training cohort, none of the patients received any form
of adjuvant therapy. Of the 485 patients used for analysis in the
testing cohort, 111 patients (22.9%) were treated with adjuvant
chemotherapy after curative resection. The regimens included
combined chemotherapy with fluorouracil, leucovorin, and
oxaliplatin (FLO) (6 cases); monotherapy with mitomycin C
(46 cases); fluorouracil derivatives (47 cases); and other
treatments (12 cases). Of the 588 patients in the validation
cohort, the regimen for 223 patients (37.9%) with postoperative
chemotherapy included combined chemotherapy with FLO (87
cases); combined chemotherapy with fluorouracil, leucovorin,
and platinol (FLP) (79 cases); combined chemotherapy with
fluorouracil and paclitaxel (FP) (11 cases); combined chemo-
therapy with etoposide, leucovorin, fluorouracil and platinol
(ELFP) (28 cases); and other treatments (18cases). Regarding the
resectable gastric cancer patients with chemotherapy, the
distributions of demographic characteristics and the selected
clinicopathologic variables of patients between FLO group and
FLP group were similar (all of P..05), except histological type
(P= .001, Table S1). In addition, 7 pathologically confirmed
gastric cancer and respective non-cancerous fresh frozen gastric
mucosa tissues from recent patients in Nantong Cancer Hospital
were obtained for Western blot analysis.
Overall survival (OS) was the primary end-point of this analysis.
Survival time was ascertained from the date of surgery to the date
of death or to the last follow-up. Date of death for each case was
obtained from patient records or patients’ families through follow-
up telephone calls and further double-verified by local civil affairs
department and public security department. Detailed clinicopath-
ologic information was obtained. Lauren’s criteria were used to
classify the tumors into intestinal type or diffuse type [21] and
staged according to the Tumor, Node, Metastasis (TNM)
guidelines [22].
Construction of Tissue Microarray (TMA) and
Immunohistochemistry
Paraffin-embedded archived tissue material of tumor and
surrounding normal gastric tissue was used for TMA construction.
TMAs were prepared as previously published [19]. In brief,
duplicate 1.0 mm diameter cores of tissue from each sample were
punched from paraffin tumor block and corresponding non-
tumoral tissues in the training cohort or from cores of primary
tumor biopsies in testing and validation cohorts. As a tissue
control, the biopsies of normal gastric epithelium tissues were
inserted in the four angles and the center of each slide.
A standard protocol was used for the immunostaining of the
TMAs. The detailed process was described earlier [19]. IHC was
performed using DO7 monoclonal antibody (1:80; Dako,
Carpinteria, CA), which detects the wild-type and mutant forms
of the p53-protein, together with ElivisionTM super HRP Kits
(Maixin-Bio, Fujian, China), applying varying detection and
antigen retrieval methods. The omission of the primary antibody
served as negative control. The staining scores of the tissue
controls in each microarray slide were pre-evaluated as a quality
control of the immunostaining.
Evaluation of Immunohistochemistry
At first, staining of p53 in the tissue were scored independently
by two pathologists blinded to the clinical data, by applying a
semi-quantitative immunoreactivity score (IRS) in the training
cohort. The scoring criteria for IRS were reported elsewhere [23].
The intensity of immunostaining was shown in Fig. S2. The
concordance for IRS staining score of p53 between the two
pathologists was 74 (90%) in 82 tumors of the training set; and the
few discrepancies were resolved by consensus using a multihead
microscope. The variability in p53 staining was 4 (5%) in the
duplicate cores of 82 tumors. These cases were stained by whole-
slide IHC and further scored.
The optimum cutoff value of IRS is obtained by receiver-
operator characteristic (ROC) analysis, and the area under the
curve (AUC) at different cutoff values of p53 IRS for 1, 3 and 5
years of overall survival time was calculated. The optimal value of
cutoff points of p53 IRS in Nantong district cohort (combined
training cohort and testing cohort) was 4 due to the predictive
value of this cutoff point for death was the best (Fig. S3). Under
these conditions, samples with IRS 0–4 and IRS 5–12 was
classified as low and high expression of p53 in tumors, respectively.
After establishing the immunohistochemical assessment criteria in
the Nantong district cohort, the expression of p53 in the Yixing
district cohort (validation cohort) was scored by the same
pathologists with the exactly same procedure.
Western Blotting
Western blotting was carried out as previously described [19].
Monoclonal mouse anti-p53 antibody (1:1000; Dako, Carpin-
teria, CA), and monoclonal mouse anti-b-actin antibody
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(1:2000; Beyotime Biotechnology, Nantong, China) were used
for the primary antibody. Immunoreactive bands were detected
with a Phototope-HRP Western blot detection kit (Cell
Signaling Technology Inc, Beverly, MA, USA). For densitomet-
ric analysis, p53 protein bands on the blots were measured by
Image J software (version 1.44, Wayne Rasband, National
Institutes of Health, USA), after normalization to the corre-
sponding b-actin level.
Statistical Analysis
The association between p53 expression and clinicopathologic
parameters was evaluated by Fisher’s exact test. The differential
expression of p53 in primary tumors and their corresponding non-
tumors were assessed by the Wilcoxon test (grouped) and
Spearman rank-order correlation (raw scores). The correlation
between the expression of p53 and JWA was established by
Spearman rank-order correlation (raw scores) and Fisher’s exact
test (grouped). Probability of differences in OS as a function of
time was ascertained by use of the Kaplan-Meier method, with a
log-rank test for significance. Univariate or multivariate Cox
regression analysis was performed to estimate the crude hazard
ratios (HRs), adjusted HRs and their 95% confidence intervals
(CIs), with adjustment for potential confounders. Then we
analyzed the predictive value of the parameters using time-
dependent ROC curve analysis for censored data and calculated
AUC of the ROC curves. We evaluated the performances of
different scores by plotting (t, AUC [t]) for different values of
follow-up time (t). All the statistical analyses were performed by
Statistical Analysis System software (version 9.1.3; SAS Institute,
Cary, NC), STATA statistical software (version 10.1; StataCorp,
College Station, TX), and R software (version 2.10.1; The R
Foundation for Statistical Computing). A p-value of ,.05 was
deemed statistically significant.
Figure 1. Correlation of p53 expression in primary tumors and corresponding non-tumors in gastric cancer patients. (A) p53 protein
levels in 7 cancer tissues and paired non-cancerous normal tissues of gastric cancer patients were analyzed by Western blotting. The level of each
protein was normalized against b-actin, and the protein levels in cancer tissues indicated as a ratio to paired non-cancerous normal tissues. Note: N,
non-cancerous normal tissue; T, Tumor tissue. (B) Representative immunohistochemical staining for p53 in TMA. T, gastric cancerous tissue; N, paired
non-cancerous gastric tissue. Top panel: scale bar, 250 mm; bottom panel: scale bar, 50 mm. (C) The distribution of the difference of p53 staining (D
IRS = IRS T-IRS N). P values were calculated with the Wilcoxon test. IRS, immunoreactivity score.
doi:10.1371/journal.pone.0052348.g001
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Results
Increased p53 Expression in Gastric Cancer Versus
Adjacent Normal Tissues
Seven pairs of human gastric cancer samples, including
primary gastric cancer tissues and matched normal gastric
mucosa were selected to test p53 protein expression by Western
blot. Elevated expression of p53 occurred in 6 of 7 gastric
tumors compared with the paired normal gastric mucosa
(Fig. 1A). Immunohistochemical staining of gastric tissue
microarray (TMA) was used to further confirm p53 expression
in 82 gastric cancer patients in the training cohort. It was
shown that p53 staining was mainly localized in the nuclei
(Fig. 1B). The distribution of the differences of IRS for p53
expression in tumors and matched non-tumors was shown in
Fig. 1C. Moreover, p53 expression was significantly increased in
65 of 82 (79.2%) of gastric cancers compared with the matched
normal gastric tissues (P,.001, Wilcoxon test; Fig. 1C). In all
three independent cohorts of patients treated only with surgery
only, the expression of p53 was negatively correlated with JWA
in the cancerous tissues (P,.001 for all correlations, Table 1).
Correlation between p53 Expression and
Clinicopathological Features in Patients Treated with
Surgery Alone
In all three cohorts, we testified that p53 expression in
cancerous tissues was significantly correlated with lymph node
metastasis (N-category). Increased expression of p53 was closely
associated with higher TNM stage in training and testing
cohorts, but without significance in the validation cohort.
Furthermore, increased expression of p53 was notably related
to other clinicopathological characteristics, such as depth of
invasion (T-category), distant metastasis (M-category), tumor
Table 1. Correlation between expression levels of p53 and clinicopathologic features of the individuals in three cohorts of gastric
cancers treated with surgery alone.
Variables Training cohort (n =82 cases) Testing cohort (n=374 cases) Validation cohort (n=365 cases)
Low (%) High (%) pa Low (%) High (%) pa Low (%) High (%) pa
All patients 46 (56.1) 36 (43.9) 232 (62.0) 142 (38.0) 147 (40.3) 218 (59.7)
Age (years) .272 .222 .197
#65 34 (73.9) 31 (86.1) 143 (61.6) 97 (68.3) 58 (39.5) 102 (46.8)
.65 12 (26.1) 5 (13.8) 89 (38.4) 45 (31.7) 89 (60.5) 116 (53.2)
Gender .800 .729 .254
Males 35 (76.1) 26 (72.2) 163 (70.3) 97 (68.3) 109 (74.2) 173 (79.4)
Females 11 (23.9) 10 (27.8) 69 (29.7) 45 (32.7) 38 (25.8) 45 (20.6)
Depth of invasion .379 .002 .043
T1/T2 4 (8.7) 1 (2.8) 56 (24.1) 16 (11.3) 60 (40.8) 66 (30.3)
T3/T4 42 (91.3) 35 (97.2) 176 (75.9) 126 (88.7) 87 (59.2) 152 (69.7)
Lymph node metastasis ,.001 ,.001 .021
N0 19 (41.3) 1 (2.8) 87 (37.5) 17 (12.0) 67 (45.6) 72 (33.0)
N1/N2/N3 27 (58.7) 35 (97.2) 145 (62.5) 125 (88.0) 80 (54.4) 146 (67.0)
Distant metastasis .003 1.000 .173
M0 43 (93.5) 24 (66.7) 221 (95.3) 136 (95.8) 144 (98.0) 207 (95.0)
M1 3 (6.5) 12 (33.3) 11 (4.7) 6 (4.2) 3 (2.0) 11 (5.0)
TNM stage ,.001 ,.001 .057
I 8 (17.4) 1 (2.8) 35 (15.1) 5 (3.5) 47 (32.0) 46 (21.1)
II 15 (32.6) 3 (8.3) 62 (26.7) 19 (13.4) 35 (23.8) 46 (21.1)
III 18 (39.1) 17 (47.2) 107 (46.1) 91 (64.1) 62 (42.2) 119 (54.6)
IV 5 (10.9) 15 (41.7) 28 (12.1) 27 (19.0) 3 (2.0) 7 (3.2)
Tumor diameter .119 ,.001 .334
#5 cm 27 (58.7) 14 (38.9) 111 (47.8) 40 (28.2) 88 (59.9) 119 (54.6)
.5 cm 19 (41.3) 22 (61.1) 121 (52.2) 102 (71.8) 59 (40.1) 99 (45.4)
Histological typeb 1.000 .003 .082
Intestinal 24 (52.2) 18 (50.0) 146 (62.9) 66 (46.5) 68 (47.2) 82 (37.8)
Diffuse 22 (47.8) 18 (50.0) 86 (37.1) 76 (53.5) 76 (52.8) 135 (62.2)
JWA expression ,.001 ,.001 ,.001
Low 17 (37.0) 33 (91.7) 32 (13.8) 134 (94.4) 40 (27.2) 145 (66.5)
High 29 (63.0) 3 (8.3) 200 (86.2) 8 (5.6) 107 (72.8) 73 (33.5)
aTwo-sided Fisher’s exact tests.
bExcluded 4 patients with mixed intestinal and diffuse types in validation cohort.
doi:10.1371/journal.pone.0052348.t001
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diameter and histological type in respective cohort. Interestingly,
in all patients treated with surgery alone (n= 817), we found
more intestinal-type patients showed low while more diffuse-type
patients showed high p53 expression (P,.001, data not shown).
Expression of p53 had no correlation with age and gender
(Table 1).
Correlation of p53 Expression and OS in Patients Treated
with Surgery Alone
In the training cohort, 82 primary tumor samples suitable for
analysis showed a statistically significant negative correlation
between p53 expression and overall 5-year survival using Kaplan-
Meier survival curves (P,.001). These findings were validated in
two independent and larger cohorts of gastric cancer patients with
minimum five years follow-up (n= 374 and n= 365, respectively)
(Fig. 2A–C). Other significant negative predictors for survival by
Figure 2. Survival curves according to expression pattern of p53 or p53/JWA in three cohorts. (A–C) Kaplan-Meier curves depicting
overall survival according to expression pattern of p53. (D–F) Kaplan-Meier curves depicting overall survival according to expression pattern of p53/
JWA. P values were calculated with the log-rank test.
doi:10.1371/journal.pone.0052348.g002
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univariate analysis in the three independent cohorts were lymph
node metastasis (N-category, P,.01 for all, Table S2) and clinical
TNM stage (P#.001 for all, Table S2).
The multivariate Cox regression analysis indicated that low
p53 expression was an independent positive prognostic factor
for gastric cancer in all three cohorts (P,.001 for all, Table 2).
To further evaluate the prognostic value of p53 expression, we
conducted a time-dependent ROC analysis for the censored
data, which indicated that combination of clinical risk score
(TNM stage, histological type and tumor diameter) and p53
contributed much more than clinical parameters alone in both
training and testing cohorts (Fig. 3). For example, in the testing
cohort, the AUC at year 5 was 0.707 (95% CI=0.653–0.761)
for clinical risk score, whereas it was significantly increased to
0.856 (95% CI= 0.818–0.894) when combined with p53 risk
score. However, this effect was not significant in the validation
cohort due to the relatively higher AUC (about 0.8) of clinical
predictors (Fig. S4).
Correlation between p53 Expression and OS in Patients
with Adjuvant Chemotherapy
In testing and validation cohorts, OS was analyzed between the
patients who received adjuvant chemotherapy versus those who
did not. Data showed no difference in OS between surgery only
group and any regimen of postoperative adjuvant chemotherapy
(data not shown) except in the group receiving fluorouracil-
leucovorin-oxaliplatin (FLO) (n = 87, log-rank test, P= .032, Fig. 4).
A multivariate Cox regression analysis including six variables (age,
gender, TNM stage, histological types, tumor diameter and
chemotherapy) was performed to indicate the benefit of chemo-
therapy on OS. There was a statistically significant benefit for
Figure 3. ROC analyses for clinical risk score, or the combination of p53 or p53 plus JWA. (A) Time-dependent ROC analyses in the
training cohort. (B) Time-dependent ROC analyses in the testing cohort. AUC= area under the curve.
doi:10.1371/journal.pone.0052348.g003
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those who received FLO chemotherapy after operation over the
surgery alone group (HR=0.55; 95% CI=0.37–0.82, data not
shown). Notably, this effect was only found in patients with high
p53 expression where adjuvant FLO obviously increased OS as
compared with surgery alone (HR=0.56; 95% CI= 0.35–0.89,
Table S3; Log-rank test, P= .014, Fig. 4).
We also analyzed the significance of another platinum-based
chemotherapy, fluorouracil-leucovorin-platinol (FLP) regimen
(n = 79) in resectable gastric cancer. The results did not present
a significant survival difference (log-rank test, P= .134, Fig. S5),
whereas patients with low p53 expression receiving FLP regimen
even displayed a worse survival compared with those receiving
surgery only (P= .003, Fig. S5). Moreover, patients undergoing
FLP treatment with high p53 expression had no significant
survival discrepancy compared to those with surgery alone
(P= .648, Fig. S5). Further multivariate analysis elucidated that
higher risk for mortality was observed in patients with low p53
expression receiving FLP treatment compared with surgery only
(HR=1.91, 95% CI=1.08 to 3.36, Table S4).
Synergetic Effect of p53 with JWA Expression on OS in
Patients Treated with Surgery only or Adjuvant
Chemotherapy
The patients with surgery alone were further stratified into three
distinct groups on the basis of staining for p53 and JWA: p53 high
with JWA low, p53 low with JWA high and both high or both low.
It was shown that patients with p53 low and JWA high had a best
outcome of survival in these three groups (P,.001, log-rank test;
Fig. 2D–F). The multivariate Cox regression analysis demonstrat-
ed that combined expression of low p53 and high JWA was
independent positive prognostic factor for gastric cancer in all
three cohorts (P,.001 for all, Table 2). To further evaluate the
prognostic value of p53 plus JWA expression, we conducted
another time-dependent ROC analysis, which indicated that the
combination of the clinical risk score and p53 plus JWA
contributed more than the cooperation of clinical risk score with
only p53 in both of training and testing cohorts (Fig. 3). For
instance, in the training cohort, the AUC at year 5 was 0.568 (95%
CI= 0.400–0.737) for clinical risk score plus p53 risk score,
whereas it was significantly increased to 0.865 (95% CI= 0.786–
0.944) when combination of the clinical risk score with p53 plus
JWA risk score was used. However, this effect was again not
apparent in the validation cohort due to the reason mentioned
above (Fig. S4).
Based on contribution of p53 expression level to chemotherapy
outcome, we stratified such patients in coordination with JWA as
follows: FLO treatment group with high p53 expression was
divided into p53 high with JWA low and p53 high with JWA high;
and FLP treatment group with low p53 expression was also
classified into p53 low with JWA low and p53 low with JWA high.
OS was reevaluated between these subgroups. However, no
evident survival disparity was presented in synergic pattern with
JWA (Fig. S6).
Discussion
Gastric cancer is a heterogeneous disease where the outcome
varies even in patients with similar clinical and pathological
features. Even with surgery in early stages, the prognosis may be
dismal, and adjuvant chemotherapy is effective only in subgroups
of patients. New molecular markers are needed as traditional
staging systems for gastric cancer are insufficient for predicting
outcomes [24]. In this study, we recorded and demonstrated that
high expression of p53 was significantly correlated with unfavor-
able clinicopathologic parameters and decreased overall patient
survival. Furthermore, patients with high p53 expression in tumors
Table 2. Multivariate Cox regression analysis of p53 or p53/JWA expression and clinicopathologic variables predicting survival in
three cohorts of gastric cancers treated with surgery alone.
Variables
Training cohort
(n =82cases)
Testing cohort
(n =374cases)
Validation cohort
(n =365cases)
HR (95% CI) Pa HR (95% CI) Pa HR (95% CI) Pa
p53
Age (#65 vs. .65) 1.49 (0.75–2.95) .256 1.16 (0.89–1.51) .262 0.84 (0.63–1.12) .242
Gender (male vs. female) 1.58 (0.89–2.83) .120 1.01 (0.77–1.32) .950 1.17 (0.83–1.64) .365
Histological type (diffuse vs. intestinal) 1.11 (0.63–1.96) .720 1.12 (0.86–1.44) .397 1.53 (1.10–2.13) .011
Tumor diameter (#5 cm vs. .5 cm) 0.89 (0.52–1.50) .657 1.49 (1.10–2.01) .011 1.46 (1.08–1.97) .014
TNM stage (I–II vs. III/IV) 1.98 (0.95–4.13) .069 1.48 (1.05–2.07) .023 4.15 (2.85–6.03) ,.001
p53 expression (low vs. high) 6.92 (3.50–13.68) ,.001 6.17 (4.64–8.21) ,.001 1.85 (1.34–2.56) ,.001
p53/JWA
Age (#65 vs. .65) 1.45 (0.73–2.87) .290 1.19 (0.91–1.54) .203 0.83 (0.62–1.11) .216
Gender (male vs. female) 1.87 (1.03–3.39) .039 0.96 (0.73–1.25) .750 1.14 (0.81–1.61) .439
Histological type (diffuse vs. intestinal) 1.05 (0.61–1.80) .859 0.97 (0.75–1.25) .819 1.46 (1.05–2.04) .024
Tumor diameter (#5 cm vs. .5 cm) 0.99 (0.57–1.70) .959 1.51 (1.11–2.05) .008 1.51 (1.12–2.03) .007
TNM stage (I–II vs. III/IV) 0.79 (0.34–1.83) .578 1.36 (0.97–1.91) .076 3.97 (2.72–5.79) ,.001
p53/JWA expression
(p53 high JWA low vs. both low/high )
0.24 (0.11–0.49) ,.001 0.57 (0.40–0.83) .003 0.79 (0.57–1.11) .176
(p53 high JWA low vs. p53 low JWA high) 0.05 (0.02–0.14) ,.001 0.12 (0.09–0.16) ,.001 0.45 (0.30–0.67) ,.001
aMultivariate Cox regression analysis including age, gender, TNM stage, tumor diameter, histological type, p53 or p53/JWA proteins expression status.
Abbreviations: HR: hazard ratio; CI: confidence interval.
doi:10.1371/journal.pone.0052348.t002
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acquired remarkable survival benefit from adjuvant first-line
platinum-based chemotherapy (FLO or FLP). The synergy
between p53 and JWA in predicting patient outcome was
demonstrated, while no obvious elevated predictive value
concerning chemotherapy was observed.
In the present study, we found evidently increased expression of
p53 protein in gastric cancer tissues versus matched normal
mucosa, suggesting a potentially important status of p53 in gastric
carcinogenesis. Reportedly, the p53 gene is mutated in nearly 50%
of all human tumors including gastric cancer [25] and the mutated
protein remains within the cells for a longer time, allowing
detection by immunohistochemistry [26,27]. Therefore, it is
generally accepted that positive staining mainly represents the
mutant forms of p53, whereas wild-type p53 protein is degraded
more rapidly and appears weak or negative staining [10,26]. Our
data were consistent with studies from other investigators, which
revealed that positive p53 expression was associated with
unfavorable clinicopathologic characteristics and a poor prognosis
of gastric cancer patients who have undergone curative gastrec-
tomy [28–30]. It’s worth noting that some differences in
clinicopathologic features exist between Nantong and Yixing
cohorts. Since Nantong Cancer Hospital is a cancer special
hospital while Yixing People’s Hospital is a comprehensive one,
patients in the former are often at more advanced stage compared
to the latter. Accordingly, patients in Nantong cohort showed
worse clinicopathologic characteristics. Additionally, p53 and JWA
expression were only detected in tissues here but not in blood or
serum of gastric cancer patients, due to they are not secreted
proteins. Interestingly, a previous study showed a strong correla-
tion between high p53 auto-antibodies in serum of gastric
adenocarcinoma patients and poor prognosis, lymph node
metastasis and low differentiation [31]. Moreover, it was shown
that p53 expression in gastric cancer tissues correlated with serum
p53 antibodies [32]. We did not have sera collected for a similar
analysis, but this would be very interesting as a blood test is simpler
and probably more reproducible than immonohistochemistry. As
for JWA, a serum test is still pending and needs to be
demonstrated in the future.
A fascinating and important question attracting us most is
why could high expression of p53 play precisely opposite roles
on prognostic and predictive effect. This phenomenon could be
attributed to different forms of p53 and their distinct properties
in cancer biology and treatment resistance. It is widely known
mutant p53 proteins are highly expressed in many cancers and
Figure 4. Survival curves according to p53 expression in the validation cohort treated with or without FLO. P values were calculated
with the log-rank test. Note: S, surgery alone; FLO, fluorouracil-leucovorin-oxaliplatin.
doi:10.1371/journal.pone.0052348.g004
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contribute to malignant transformation, proliferation, and
metastasis in part by inhibiting wild-type p53 as well as other
members of p53 family [6,33]. Mouse models bearing knock-in
mutations of p53 showed that mutant p53 proteins can drive
tumor formation, invasion and metastasis through dominant
negative inhibition of wild-type p53 along with gain-of-function
or ‘neomorphic’ activities that can inhibit or activate the
function of other proteins [34,35]. Likewise in our study, high
p53 expression in gastric tumors correlated with lymph node
metastasis, higher TNM stage and other unfavorable clinico-
pathologic features, leading to a more aggressive phenotype with
a worse prognosis when untreated. In contrast, the positive
predictive effect of high p53 expression on survival in both
platinum treated patients may point to a dual role of p53 in
chemo-resistance. Currently, a major obstacle in platinum
chemotherapy is the repair of platinum-damaged DNA that
results in increased resistance, reduced apoptosis, and finally
treatment failure. Wild-type p53 may partially play such a role
during this process via cell cycle arrest and following repair of
damage induced by chemical agents [36–39]. Conversely,
mutant p53 proteins are unable to function in DNA damage
repair as their wild-type counterpart where the patients become
more sensitive to chemicals [36,40,41]. However, the detailed
mechanism of mutant p53 in platinum treatment needs to be
further investigated. It must be noted that the patients received
more survival benefit from FLO than from FLP, which may be
partially due to that FLO reduces toxicity as compared with
FLP as noted before [19].
JWA is a typical stress response gene as well as a tumor
suppressor [18,42]. In vitro and in vivo studies confirmed that loss
of JWA suppressed cell differentiation and increased cell migration
and metastasis [42–44]. Our latest results manifested low JWA
expression in gastric tumors correlated with unfavorable clinico-
pathologic indicators but better chemotherapy outcome [19]. In
the present study, we found that JWA improved the prognostic
value of p53, suggesting that loss of JWA combined with p53
mutation may increase tumor aggressiveness and metastasis, which
probably because JWA is also a member of DNA repair pathway
and possibly play a mutual role in gastric carcinogenesis.
Intriguingly, even if both markers separately were predictive for
platinum treatment, the combination did not improve the
predictive value, but this result is hampered by small group of
patients in the subgroups. A larger number of patients receiving
platinum-based chemotherapy regimens should be included in our
future study to further validate our results. Furthermore, no direct
regulatory effect was demonstrated between p53 and JWA (data
not shown), perhaps they act in different repair pathways
[17,18,45–48] and indirect relationship exists between them under
certain situations. Moreover, p53 and JWA may synergistically
regulate the same molecules or signal pathways which needs to be
elucidated in further studies.
In summary, we revealed a combined value of tumoral p53 with
JWA as efficient prognostic factors for the first time, to the best of
our knowledge. Although a definite co-action of these two proteins
is yet to be proven, it may provide the potential predictors for
adjuvant chemotherapy with a platinum-based regimen.
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